Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. involving ADU-1805, an innovative anti-SIRP? antibody ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA ...

Monash University has secured over $49 million in funding for 40 projects in the latest round of NHMRC Ideas Grants - more than any other university ...